Navigation Links
Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
Date:10/30/2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of rheumatoid arthritis (RA). Physicians have a strong preference for the more established, market-leading TNF-alpha inhibitors, Amgen/Pfizer's Enbrel and AbbVie's Humira, over other biologic agents and Xeljanz.  Surveyed physicians rated Enbrel and Humira highest in product satisfaction, perceive these agents as having the most favorable benefit/risk profiles, and they indicate that both products outperform other TNF-alpha inhibitors on the most important stated attributes to prescribing RA therapies. Consequently, these two biologic therapies are used typically as first- or second-line biologic treatment after conventional disease-modifying antirheumatic drug (DMARD) therapy failure.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends®:Rheumatoid Arthritis (US) report finds that rheumatologists participating in this study also rated Xeljanz, the newest entrant in the RA market, moderately. However, Xeljanz was rated significantly lower than all biologics on overall product performance. In addition, Xeljanz has yet to carve out a distinct place in the RA treatment algorithm. Physicians reported using the product most often after one to three TNF-alpha inhibitor failures. The report also finds that only 14 percent of Xeljanz patients were biologic naive.

"Xeljanz was on the market 9 months at the time this study was fielded, so rheumatologists may not be certain as to which patient types would benefit most from Xeljanz, which is why they are trying it on different patient types at various points in the treatment algorithm," said BioTrends Senior Director Greta Unger. "A relatively low percentage of Xeljanz patients were biologic naive even though it has been approved for use in this patient group. It will be interesting to see if physicians' behavior changes over time as they gain more experience with the product."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
2. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
3. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
6. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
7. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
8. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
9. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
10. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2019)... ... June 12, 2019 , ... Through their Sidewalk Angels Foundation (SWA), Marisol ... importance of protecting your entire family from Lyme and other tick-borne diseases. We are ... fur we have. , Through this partnership SWA and GLA look to raise ...
(Date:6/11/2019)... ... , ... Today NASH kNOWledge hosted a Liver Disease Information ... Steatohepatitis (NASH) Day, a global effort in the fight against NASH. Community leaders ... what they can do to help. The event also included a pre-screening of ...
(Date:6/11/2019)... China, and SAN DIEGO (PRWEB) , ... June ... ... and fully integrated global Contract Development and Manufacturing Organization (CDMO) serving the global ... announced the appointment of Wei Chen, Ph.D as the company's new Chief Executive ...
Breaking Medicine Technology:
(Date:6/14/2019)... N.J. (PRWEB) , ... June 14, 2019 , ... FL Top Docs is proud to present the following recently reviewed and approved providers for May ... Dietrick , BREAST SURGERY, Dr. Debbie Berlin ... Khan , Dr. Christopher J. Pastore , Dr. Yamilet Tirado ...
(Date:6/13/2019)... ... ... painful, inflammatory disease that occurs when tissue grows outside of the uterus. The symptoms of ... , Irregular menstruation , Severe cramps , Back pain ... treatment protocols in dealing with the symptoms of endometriosis. In the past, a total hysterectomy, ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... Women’s Excellence in Obstetrics and Gynecology specializes ... conditions, some that may be difficult to diagnosis. Women’s Excellence handles routine and complicated ... cysts , Endometriosis , Heavy periods , Adhesions (scar ...
(Date:6/13/2019)... ... June 13, 2019 , ... In Partnership with the ... for low-income, underinsured individuals at its Mesquite, TX office on July 13th. , Dental ... cleanings and extractions . For more information, please visit the Monarch ...
(Date:6/13/2019)... ... , ... Hard money lenders like Monroe Funding Corporation are able to respond ... provided quickly. If the documentation and collateral are immediately available, it’s possible to receive ... oversight involved with a traditional lender, which allows loans to be customized and adjusted ...
Breaking Medicine News(10 mins):